Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Receivables: 2020-2023

Historic Receivables for Rocket Pharmaceuticals (RCKT) over the last 1 years, with Dec 2023 value amounting to $50,000.

  • Rocket Pharmaceuticals' Receivables was N/A to $50,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $3.0 million, marking a year-over-year change of. This contributed to the annual value of $50,000 for FY2023, which is N/A change from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Receivables stood at $50,000 for Q4 2023, which was down 94.44% from $900,000 recorded in Q1 2022.
  • In the past 5 years, Rocket Pharmaceuticals' Receivables registered a high of $1.6 million during Q2 2020, and its lowest value of $50,000 during Q4 2023.
  • Its 3-year average for Receivables is $737,500, with a median of $950,000 in 2021.
  • Data for Rocket Pharmaceuticals' Receivables shows a maximum YoY tumbled of 37.50% (in 2021) over the last 5 years.
  • Quarterly analysis of 4 years shows Rocket Pharmaceuticals' Receivables stood at $1.1 million in 2020, then slumped by 37.50% to $1.0 million in 2021, then dropped by 10.00% to $900,000 in 2022, then reached $50,000 in 2023.
  • Its Receivables stands at $50,000 for Q4 2023, versus $900,000 for Q1 2022 and $1.0 million for Q2 2021.